Haemonetics Co. (NYSE:HAE - Get Free Report) hit a new 52-week low during mid-day trading on Monday after JMP Securities lowered their price target on the stock from $125.00 to $100.00. JMP Securities currently has a market outperform rating on the stock. Haemonetics traded as low as $58.80 and last traded at $59.88, with a volume of 221474 shares. The stock had previously closed at $59.34.
HAE has been the subject of several other reports. JPMorgan Chase & Co. started coverage on shares of Haemonetics in a report on Friday, December 6th. They set an "overweight" rating and a $116.00 price objective for the company. Needham & Company LLC decreased their target price on shares of Haemonetics from $112.00 to $108.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Barrington Research lowered their price target on Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Bank of America lowered Haemonetics from a "neutral" rating to an "underperform" rating and cut their price objective for the stock from $95.00 to $68.00 in a report on Friday, February 7th. Finally, Raymond James raised Haemonetics from an "outperform" rating to a "strong-buy" rating and set a $120.00 target price on the stock in a report on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $101.67.
Check Out Our Latest Stock Report on Haemonetics
Institutional Investors Weigh In On Haemonetics
Several large investors have recently bought and sold shares of the business. Wellington Management Group LLP grew its position in Haemonetics by 9.5% in the third quarter. Wellington Management Group LLP now owns 4,201,565 shares of the medical instruments supplier's stock worth $337,722,000 after acquiring an additional 363,702 shares in the last quarter. Thrivent Financial for Lutherans boosted its holdings in shares of Haemonetics by 14.9% in the 4th quarter. Thrivent Financial for Lutherans now owns 1,264,294 shares of the medical instruments supplier's stock worth $98,716,000 after purchasing an additional 164,111 shares during the period. Royce & Associates LP increased its position in shares of Haemonetics by 2.6% during the 3rd quarter. Royce & Associates LP now owns 1,210,546 shares of the medical instruments supplier's stock valued at $97,304,000 after purchasing an additional 30,868 shares during the last quarter. Geode Capital Management LLC raised its holdings in Haemonetics by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,193,927 shares of the medical instruments supplier's stock valued at $95,986,000 after buying an additional 21,547 shares during the period. Finally, Boston Trust Walden Corp raised its holdings in Haemonetics by 13.1% during the 4th quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier's stock valued at $71,500,000 after buying an additional 106,114 shares during the period. Institutional investors own 99.67% of the company's stock.
Haemonetics Price Performance
The company has a quick ratio of 2.09, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. The company has a market capitalization of $3.13 billion, a PE ratio of 24.51, a price-to-earnings-growth ratio of 0.98 and a beta of 0.39. The firm's 50 day simple moving average is $74.92 and its 200 day simple moving average is $77.69.
Haemonetics (NYSE:HAE - Get Free Report) last released its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, research analysts anticipate that Haemonetics Co. will post 4.59 EPS for the current fiscal year.
About Haemonetics
(
Get Free Report)
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
See Also
Before you consider Haemonetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.
While Haemonetics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
